Global market for contract manufacturing of living biotherapeutic products and microbiomes to be worth $2.60 billion by 2030 - World News Report

Global market for contract manufacturing of living biotherapeutic products and microbiomes to be worth $2.60 billion by 2030 – World News Report

Information on the global market for living biotherapeutic products and microbiome contract manufacturing

The global contract manufacturing market for living biotherapeutic products and the microbiome is valued at $355.9 million in 2021.

The key players in this market are Quay Pharmaceuticals, Cobra Biologics Limited, Cerbios-Pharma SA, List Biological Labs, Inc., Arranta Bio, BacThera, Luina Bio Pty Ltd, 4D pharma plc, Paras.”

— Insight Analyst

NEW JERSEY, SUTT, NEW YORK, USA, September 1, 2022 /EINPresswire.com/ — InsightAce Analytic Pvt. Ltd. announced the publication of a market research report titled “Global Contract manufacturing of living biotherapeutic products and the microbiome Market (by products (API, FDF), product type (solid preparations, oral liquids, injectables, others), scale of operations (preclinical scale operations, clinical scale operations, commercial scale operations), company size (small Companies, Medium Companies , Large Companies)) – Market Overview and Industry Analysis 2030″

Get a demo copy of the Global Live Biotherapy & Microbiome Contract Manufacturing Market Report at https://www.insightaceanalytic.com/request-sample/1152

According to the company’s latest research, the global market for contract manufacturing of living biotherapeutic products and microbiomes is valued at US$355.9M in 2021 and is projected to reach US$2608.0M in 2030, with a projected CAGR of 25.2% between 2022 and 2030.

The collection of many bacteria that live in and in the human body is known as the human microbiome. For example, the skin, intestines, mouth, and vagina all have microbiomes. The use of LBP and microbiome therapy has opened up new possibilities and perspectives that are directly related to the goals of sustainable development. Microbiome therapy developers are actively outsourcing some manufacturing operations while enhancing their own skills due to complex manufacturing procedures, the need to improve GMP manufacturing facilities, and a lack of innate experience. Unlike vaccines, live biotherapeutics contain living organisms, such as bacteria. These products can be used to prevent, treat or cure human diseases or conditions. Specific abnormalities of the microbiome, known as dysbiosis, are associated with health problems, and this is likely due to the loss of microbial metabolites, signaling molecules, or regulators of host processes. Inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), type 2 diabetes, obesity, and metabolic syndrome are associated with dysbiosis. LBPs exert their effects by interacting directly with the native microbiota or by altering the relationship between host and microbiota, resulting in an indirect biological effect on the patient.

As a result of the progress made in the clinical development of a range of potentially useful live microbiome-based biotherapeutic products, this upcoming therapeutic segment is expected to become one of the pharmaceutical industry’s fastest growing markets. over the next few years. Most clinical treatments are in the preclinical stage; some are in clinical development and about 15 are in phase II/III trials. The commercialization of these products in the coming years is expected to create significant market expansion potential over the expected time frame.
However, growth in this sector may stall if the pioneers do not have adequate production capacity. Market expansion is hampered by many issues, including the lack of important industry standards associated with the production of live biotherapeutics, batch-to-batch stability issues, a lack of infrastructure, and uncertainty around product approval and regulatory oversight. However, the increase in the number of production contracts between companies is expected to open up huge new opportunities for the expansion of the industry around the world. Additional challenges faced by modern inventors are related to ensuring that Good Manufacturing Practices (GMPs) and manufacturing facilities are followed.

North America is projected to grow rapidly in the coming years due to strong demand and significant impacts from COVID-19 (2022-2030). Product development and research into living biotherapeutic components receive huge funding from companies.

The key players in this market are Quay Pharmaceuticals, Cobra Biologics Limited, Cerbios-Pharma SA, List Biological Labs, Inc., Arranta Bio, BacThera, Luina Bio Pty Ltd, 4D pharma plc, Paras Biopharmaceuticals Finland Oy, Capsugel, Deerland Probiotics & Enzymes , Paragon Bioservices, UAS Labs, Biose, Cobra Biologics, Cerbios, Inpac Probiotics, BJP Laboratories, S-Biomedic, Meteoric Biopharmaceuticals, BiomX, Universal Stabilization Technologies, Assembly Biosciences, Wacker Biotech and Chung Mei Pharmaceutical. There are several players around the world in the market for living biotherapeutic products and microbiome contract manufacturing. Increasing R&D activities, as well as partnerships between key players operating in the market to find platforms from various companies, are expected to boost the market significantly in the coming years.

Inquiry before purchase: https://www.insightaceanalytic.com/enquiry-before-buying/1152

Key events in the market
• In July 2022, Quay Pharma and SGS jointly developed a new oral drug for the treatment of inflammatory bowel disease. Millions of people with Crohn’s disease and ulcerative colitis can change their lives for the better with this new oral drug. For pharmaceutical and biotechnology firms around the world, SGS Quay Pharma offers end-to-end outsourced formulation and analysis services, followed by clinical trials and commercial production.
• In June 2020, to expand the microbial platform and increase flexibility in probiotic production, Chr. Hansen acquired UAS Laboratories LLC. The acquisition does not affect the company’s ability to pay a regular dividend of 40% to 60% of net income and is fully compliant with Chr. Hansen’s capital allocation policy. Low interest bridge financing from major banks will be used to pay the purchase price.
• In April 2019, Catalent, Inc., Paragon Bioservices, Inc. and Catalent Inc. announced the signing of a legally binding agreement under which Catalent will pay $1.2 billion to buy Paragon. The deal will give Catalent shareholders the value they want, and Paragon will represent a modest part of Catalent’s business in the short term. However, over time, this acquisition will change the company’s business profile and significantly accelerate sales and EBITDA growth.

Market segmentation
Global market for contract manufacturing of living biotherapeutic products and microbiome by product manufactured, 2022-2030 (Cost, mln USD)
• API
• FDF

Global Contract Manufacturing Market for Living Biotherapeutic Products and Microbiome by Formulation Type, 2022-2030 (Cost, mln USD)
• Solid compounds
• Oral liquids
• Injectables
• Other

Global market for contract manufacturing of living biotherapeutic products and microbiome by scale of operations, 2022-2030 (Cost, mln USD)
• Operations of preclinical scaling
• Clinical scale operations
• Commercial Scale Operations

Global market for contract manufacturing of live biotherapeutic products and microbiome by company size, 2022-2030 (Cost, mln USD)
• Small companies
• Medium companies
• Large companies

Global Contract Manufacturing Market for Living Biotherapeutic Products and Microbiome by Region, 2022-2030 (Cost, mln USD)
• North America
• Europe
• Asian-Pacific area
• Latin America
• Middle East and Africa

North America Contract Manufacturing Living Biotherapy Products and Microbiome Market by Country, 2022-2030 (Cost, mln USD)
• US
• Canada

European market for contract manufacturing of living biotherapeutic products and microbiome by country, 2022-2030 (Cost, mln USD)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Contract Manufacturing of Living Biotherapeutic Products and Microbiome Market in Asia-Pacific by Country, 2022-2030 (Cost, mln USD)
• India
• China
• Japan
• South Korea
• Australia and New Zealand

Contract manufacturing of live biotherapeutic products and microbiome market in Latin America by country, 2022-2030 (Cost, mln USD)
• Brazil
• Mexico
• Rest of Latin America

Middle East and Africa Contract Manufacturing of Living Biotherapeutic Products and Microbiome Market by Country, 2022-2030 (Cost, mln USD)
• GCC countries
• South Africa
• Rest of the Middle East and Africa

Why buy this report:
 Obtain a comprehensive analysis of the prospects for the global market for contract manufacturing of living biotherapeutic products and the microbiome.
 Get an overview of the industry and future market trends for contract manufacturing of living biotherapeutic products and the microbiome.
 Analyze the drivers and challenges of the global market for living biotherapeutic products and microbiome contract manufacturing.
 Obtain information on the global market size forecast for living biotherapeutic products and microbiome contract manufacturing (value in million USD) until 2030.
 To obtain information about investments, mergers and acquisitions in the industry of the global contract manufacturing market for living biotherapeutic products and the microbiome.

For more information @ https://www.insightaceanalytic.com/customization/1152

Priyanka Tilekar
Insightace Analytic Pvt. OOO
+1 551-226-6109
write to us here

.

Tags: ,
Previous Post
Trends, Strategies and Opportunities in the Global Microelectromechanical Systems Market for 2022-2031
Blog

Trends, Strategies and Opportunities in the Global Microelectromechanical Systems Market for 2022-2031

Next Post
Russia calls aging space station 'dangerous' as successor plans
Blog

Russia calls aging space station ‘dangerous’ as successor plans

Leave a Reply

Your email address will not be published. Required fields are marked *